Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.

• From 1995 to 2003, 603 adult patients from Sweden and Norway with metastatic testicular nonseminomatous germ cell tumor (NSGCT) were included prospectively in a population-based protocol with strict guidelines for staging, treatment, and follow-up. Patients with extragonadal primary tumor or previous treatment for contralateral testicular tumor were excluded. The basic strategy was to individualize treatment according to initial tumor marker response.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Adolescent

Adult

Aged

Antineoplastic Combined Chemotherapy Protocols

therapeutic use

Bleomycin

therapeutic use

Cisplatin

therapeutic use

Drug Administration Schedule

Etoposide

therapeutic use

Humans

Male

Middle Aged

Neoplasm Metastasis

Neoplasms

Germ Cell and Embryonal

drug therapy

mortality

pathology

Norway

Population Surveillance

Prognosis

Sweden

Testicular Neoplasms

drug therapy

mortality

pathology

Tumor Markers

Biological

analysis

Publikations- och innehållstyp

vet (ämneskategori)

art (ämneskategori)